Astellas builds its R&D footprint in Cambridge/Boston with an add-on for labs, offices

Astel­las is snap­ping in an­oth­er piece of the re­al es­tate puz­zle for its glob­al R&D re­or­ga­ni­za­tion.

Just as it wraps one project to piece to­geth­er its parts in the Bay Area, the Japan­ese phar­ma play­er has found a new home for a slate of groups op­er­at­ing in the all-im­por­tant Cam­bridge/Boston hub.

Astel­las signed up for two floors of the 375,000-square-foot 441 Mor­gan Av­enue de­vel­op­ment, a big project by Di­v­coW­est, with plans to cut the rib­bon on new lab and of­fice space in the mid­dle of next year. The 10-sto­ry build­ing is part of Cam­bridge Cross­ing, the sprawl­ing 43-acre de­vel­op­ment sit­ed at the join­ing of Cam­bridge, Somerville, and Boston.

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.